アクセス数 : ?
ダウンロード数 : ?
ID 115625
著者
キーワード
Insulin icodec
Phase II clinical trial
Treating to target in type 2 diabetes (4-T) trial
Insulin glargine
Food and drug administration (FDA)
資料タイプ
学術雑誌論文
抄録
There was a new report for once-weekly Novo Nordisk's insulin icodec. After subcutaneous injection, the blood concentration reaches its maximum in 16 hours, and the half-life is about 1 week. The phase II clinical trial showed i) subjects were 247 type 2 diabetes, 59.6 ± 8.9 years, BMI 31.3 ± 4.6, HbA1c 8.0 ± 0.7%, FPG 181 ± 42 mg/dL, ii) For 26 weeks, HbA1c improved from 8.1% to 6.7% in group Ico and from 8.0% to 6.9% in group Gla with no significant difference, iii) significantly markers superior to Group Ico included changes in the mean daily glucose profile and time period of 70-140 mg/dL by CGM. Insulin icodec will hopefully develop smooth next phase trial.
掲載誌名
Journal of Diabetes, Obesity & Metabolism
出版者
Yumed Text
3
2
開始ページ
e105
発行日
2020-12-24
権利情報
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License(https://creativecommons.org/licenses/by-nc-sa/4.0/).
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系